Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003394 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00003394: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003394 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003394, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of estramustine, paclitaxel, and carboplatin in treating patients with advanced prostate cancer.
Interventions
- DRUG carboplatin
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG endocrine-modulating drug therapy
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1998-04 |
| Est. Completion | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003394
The ClinicalTrials.gov registry entry for NCT00003394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003394 about?
NCT00003394 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of estramustine, paclitaxel, an...
What is the current status of trial NCT00003394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1998-04. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00003394?
The interventions under investigation include: carboplatin (DRUG), leuprolide acetate (DRUG), goserelin acetate (DRUG), endocrine-modulating drug therapy (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00003394?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.